Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
59.4 USD +0.41% Intraday chart for Incyte Corporation +1.02% -5.40%
Jun. 10 Transcript : Incyte Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM
May. 23 Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target MT

Business Summary

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:

- product sales (85.6%);

- royalties (14.2%);

- income from research and cooperation agreements (0.2%).

Number of employees: 2,524

Sales per Business

USD in Million2022Weight2023Weight Delta
Proprietary Therapeutics
100.0 %
3,395 100.0 % 3,696 100.0 % +8.87%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
95.1 %
3,200 95.6 % 3,500 95.1 % +9.38%
Europe and Japan
4.9 %
-- 179 4.9 % -

Managers

Managers TitleAgeSince
Herve Hoppenot CEO
 Chief Executive Officer 64 14-01-12
Christiana Stamoulis DFI
 Director of Finance/CFO 53 19-02-10
Steven Stein CTO
 Chief Tech/Sci/R&D Officer 57 15-03-01
Pablo Cagnoni CTO
 Chief Tech/Sci/R&D Officer 60 23-06-04
Benjamin J. Strain IRC
 Investor Relations Contact - 23-08-31
Sheila Denton LAW
 General Counsel 58 23-09-30
Thomas Tray AUD
 Comptroller/Controller/Auditor 46 05-05-31
Peter Langmuir PRN
 Corporate Officer/Principal - 15-07-31
Michael Morrissey PRN
 Corporate Officer/Principal - 15-12-31
Vijay Iyengar PRN
 Corporate Officer/Principal 51 16-04-30

Members of the board

Members of the board TitleAgeSince
Julian Baker BRD
 Director/Board Member 57 00-12-31
Edmund Harrigan BRD
 Director/Board Member 71 19-12-15
Jean-Jacques Bienaimé BRD
 Director/Board Member 70 15-01-19
Otis Brawley BRD
 Director/Board Member 64 21-09-26
Jacqualyn Fouse BRD
 Director/Board Member 62 17-11-13
Paul Clancy BRD
 Director/Board Member 62 15-01-19
Susanne Antonie Schaffert BRD
 Director/Board Member 57 22-09-30
Herve Hoppenot CEO
 Chief Executive Officer 64 14-01-12
Katherine High BRD
 Director/Board Member 72 20-03-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 224,540,751 220,631,909 ( 98.26 %) 0 98.26 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
16.26 %
36,555,160 16.26 % 2 113 M $
Baker Bros. Advisors LP
16.09 %
36,179,665 16.09 % 2 091 M $
Vanguard Fiduciary Trust Co.
10.10 %
22,715,821 10.10 % 1 313 M $
BlackRock Advisors LLC
8.344 %
18,762,652 8.344 % 1 084 M $
Dodge & Cox
6.856 %
15,416,043 6.856 % 891 M $
STATE STREET CORPORATION
4.403 %
9,899,546 4.403 % 572 M $
Renaissance Technologies LLC
2.524 %
5,676,437 2.524 % 328 M $
Geode Capital Management LLC
1.975 %
4,439,896 1.975 % 257 M $
BlackRock Life Ltd.
1.720 %
3,868,014 1.720 % 224 M $
Eaton Vance Management
1.300 %
2,922,318 1.300 % 169 M $

Holdings

NameEquities%Valuation
MERUS N.V.
6.82%
 4,004,544 6.82% 213,201,923 $

Company contact information

Incyte Corp.

1801 Augustine Cut-Off

19803, Wilmington

+302 498 6700

http://www.incyte.com
address Incyte Corporation(INCY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Incyte Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
59.4 USD
Average target price
72.8 USD
Spread / Average Target
+22.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INCYTE CORPORATION Stock Incyte Corporation
-5.40% 13.36B
CSL LIMITED Stock CSL Limited
-0.37% 92.26B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.16% 38.11B
UCB Stock UCB
+64.83% 26.51B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.98% 15.75B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.38% 11.65B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+156.85% 9.78B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.84% 10.12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+2.32% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-18.25% 7.46B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Company Incyte Corporation